Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD7L94)

• Drug Name: Palbociclib Drug Info
• Synonyms: 571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Schizophrenia	6A20	Terminated	[3]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5330286
  ChEBI ID: CHEBI:85993
  CAS Number: CAS 571190-30-2
  TTD Drug ID: DMD7L94
  VARIDT Drug ID: DR01288
  INTEDE Drug ID: DR1229
  ACDINA Drug ID: D00504

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[9]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[10]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[11]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[12]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[13]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[15]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[16]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[17]
GLR2007	DM7DWLY	Glioblastoma of brain	2A00.00	Phase 1/2	[18]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[47]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[49]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[51]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[56]

Drug(s) Targeting Cyclin-dependent kinase 6 (CDK6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[9]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[10]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[11]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[12]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[13]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[17]
GLR2007	DM7DWLY	Glioblastoma of brain	2A00.00	Phase 1/2	[18]
FCN-437	DMQ8VUW	Breast cancer	2C60-2C65	Phase 1/2	[19]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[20]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[22]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[23]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[25]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[24]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[24]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[26]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[24]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[27]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[28]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[29]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[30]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[31]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[32]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[33]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[34]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[35]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[34]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[36]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[37]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[38]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[42]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[43]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[44]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[45]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[39]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[46]

Drug(s) Affected By CCN family member 1 (CCN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[58]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[58]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[63]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]

Drug(s) Affected By Kinetochore protein NDC80 homolog (NDC80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Aurora kinase A (AURKA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[74]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[73]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]

Drug(s) Affected By Monocarboxylate transporter 5 (SLC16A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[76]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[82]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[83]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[84]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[85]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[86]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[87]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[88]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[89]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[90]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[91]

Drug(s) Affected By Protein Mis18-beta (OIP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Zinc finger protein SNAI2 (SNAI2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]

Drug(s) Affected By Protein regulator of cytokinesis 1 (PRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[97]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[98]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[99]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Hyaluronan mediated motility receptor (HMMR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[73]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Cell division control protein 45 homolog (CDC45)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[105]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[106]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]

Drug(s) Affected By Geminin (GMNN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]

Drug(s) Affected By Glutaminase kidney isoform, mitochondrial (GLS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[114]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[115]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]

Drug(s) Affected By G2/mitotic-specific cyclin-B2 (CCNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[116]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]

Drug(s) Affected By Serine protease 23 (PRSS23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[119]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[120]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Mestranol	DMG3F94	Contraception	QA21	Approved	[120]

Drug(s) Affected By Kinesin-like protein KIF20A (KIF20A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Chromosome-associated kinesin KIF4A (KIF4A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Epanova	DMHEAGL	Hypertriglyceridemia	5C80.1	Approved	[125]

Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[126]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[128]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[130]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[131]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[132]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[133]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[134]

Drug(s) Affected By Securin (PTTG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By G1/S-specific cyclin-E2 (CCNE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[136]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[99]

Drug(s) Affected By Myc proto-oncogene protein (MYC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[138]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[139]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[141]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[142]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[143]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[144]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[145]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[147]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[148]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[149]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[150]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[151]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[152]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[153]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[154]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[155]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]

Drug(s) Affected By Apolipoprotein E (APOE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[156]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[157]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[158]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Thymidine kinase, cytosolic (TK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[159]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[160]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[161]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[163]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]

Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[166]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[167]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[168]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[169]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[129]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[170]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[171]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[56]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[172]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[87]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[173]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]

Drug(s) Affected By SPARC (SPARC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[175]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[176]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[177]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[178]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[179]

Drug(s) Affected By Serine/threonine-protein kinase pim-1 (PIM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[180]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[181]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[183]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[184]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By DNA topoisomerase 1 (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[148]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[185]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[106]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[186]

Drug(s) Affected By DNA topoisomerase 2-alpha (TOP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[187]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[188]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[190]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[191]

Drug(s) Affected By Proliferating cell nuclear antigen (PCNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[193]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[194]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[195]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[196]

Drug(s) Affected By Cadherin-1 (CDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[197]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[93]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[198]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[199]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[200]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[201]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[202]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]

Drug(s) Affected By Tissue factor (F3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[203]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[204]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[205]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[206]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[207]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[208]
Fructose	DM43AN2	Vomiting	MD90	Approved	[209]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[210]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[204]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[175]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[172]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[87]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[211]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[212]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]

Drug(s) Affected By Elastin (ELN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[213]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[214]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[215]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[217]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[219]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[148]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[220]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[221]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[222]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[223]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[224]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[225]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[226]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[227]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[185]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[228]

Drug(s) Affected By Stathmin (STMN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[139]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[229]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[230]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[231]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[232]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Cadherin-2 (CDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[234]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[235]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[236]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[237]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[238]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[239]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[240]

Drug(s) Affected By Cyclin-A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[241]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[172]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[140]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[194]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[242]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[243]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]

Drug(s) Affected By Lamin-B1 (LMNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[244]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[245]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[246]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[247]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Ribonucleoside-diphosphate reductase large subunit (RRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[248]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[163]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Alanine aminotransferase 1 (GPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[148]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[249]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[250]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[148]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[148]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[148]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[251]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[6]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[6]

Drug(s) Affected By Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[172]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[252]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[253]
Selenium	DM25CGV	N. A.	N. A.	Approved	[48]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[211]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[254]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[255]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]

Drug(s) Affected By High mobility group protein B2 (HMGB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[256]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[257]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]

Drug(s) Affected By Retinoblastoma-like protein 1 (RBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[258]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[259]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]

Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[261]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[262]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[263]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[264]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[265]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]

Drug(s) Affected By M-phase inducer phosphatase 1 (CDC25A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[266]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[52]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[267]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[268]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[269]

Drug(s) Affected By M-phase inducer phosphatase 3 (CDC25C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[115]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[270]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[271]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]

Drug(s) Affected By Ribonucleoside-diphosphate reductase subunit M2 (RRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[248]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[274]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[275]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[276]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[277]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[278]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[279]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[280]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[193]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[143]

Drug(s) Affected By Dual specificity protein kinase TTK (TTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]

Drug(s) Affected By DNA replication licensing factor MCM7 (MCM7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[243]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Catenin beta-1 (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[281]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[282]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[68]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[283]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[284]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[285]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[286]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[239]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[287]

Drug(s) Affected By Receptor-type tyrosine-protein kinase FLT3 (FLT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[288]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[289]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[119]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[290]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[291]
Venetoclax	DM8I94Y	Chronic lymphocytic leukaemia	2A82.0	Approved	[292]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[293]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[294]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[136]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[256]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[189]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[84]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[296]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[87]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[297]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[211]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]

Drug(s) Affected By Flap endonuclease 1 (FEN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Replication factor C subunit 5 (RFC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[298]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[299]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]

Drug(s) Affected By Cyclin-F (CCNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[259]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Lamina-associated polypeptide 2, isoform alpha (TMPO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[300]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[301]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[302]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[303]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[304]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[305]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[306]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[307]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[308]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[309]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[310]

Drug(s) Affected By Ran-specific GTPase-activating protein (RANBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[311]

Drug(s) Affected By Proliferation marker protein Ki-67 (MKI67)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[312]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[300]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[313]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[117]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[314]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[237]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[315]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[261]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[297]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[316]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[317]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[318]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[319]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[320]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[321]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[322]

Drug(s) Affected By Histone H3-like centromeric protein A (CENPA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[106]

Drug(s) Affected By Centromere protein F (CENPF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[323]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By DNA primase small subunit (PRIM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]

Drug(s) Affected By Serine/threonine-protein kinase Nek2 (NEK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Importin subunit alpha-1 (KPNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[324]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[325]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[326]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By Kinesin-like protein KIF11 (KIF11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Serine/threonine-protein kinase PLK1 (PLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[327]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By DNA polymerase epsilon subunit 2 (POLE2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[104]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Small ribosomal subunit protein uS14 (RPS29)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[328]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[329]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[330]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[331]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[332]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[333]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[334]

Drug(s) Affected By Histone H4 (H4C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[113]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[335]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[158]

Drug(s) Affected By G-protein-signaling modulator 2 (GPSM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[336]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Promegestone	DMK4S8I	Gynecological disease	GA6Z	Approved	[337]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]

Drug(s) Affected By Centromere-associated protein E (CENPE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]

Drug(s) Affected By Kinesin-like protein KIF23 (KIF23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[338]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Forkhead box protein M1 (FOXM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[287]

Drug(s) Affected By Retinoblastoma-like protein 2 (RBL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[339]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[340]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[336]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[341]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[342]

Drug(s) Affected By Tastin (TROAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[343]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[344]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]

Drug(s) Affected By Cell division cycle protein 20 homolog (CDC20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[345]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]

Drug(s) Affected By Laminin subunit beta-3 (LAMB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[58]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[58]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[346]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Laminin subunit gamma-2 (LAMC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[347]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[348]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[114]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[349]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By DNA polymerase alpha subunit B (POLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By Transcription factor E2F2 (E2F2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[56]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Max dimerization protein 4 (MXD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[106]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[336]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[350]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[92]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[351]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[350]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[352]

Drug(s) Affected By Maternal embryonic leucine zipper kinase (MELK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By PCNA-associated factor (PCLAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[353]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Condensin complex subunit 1 (NCAPD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[99]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By Kinesin-like protein KIF14 (KIF14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[73]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Disks large-associated protein 5 (DLGAP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[99]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[99]

Drug(s) Affected By SCL-interrupting locus protein (STIL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[344]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[354]

Drug(s) Affected By Histone-lysine N-methyltransferase EZH2 (EZH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[225]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[300]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[355]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[356]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[357]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 3 (CDKN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]

Drug(s) Affected By Laminin subunit alpha-3 (LAMA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[247]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[247]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[99]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[215]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[99]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[99]

Drug(s) Affected By Centrosomal protein of 55 kDa (CEP55)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[358]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Borealin (CDCA8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[360]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By PHD finger protein 19 (PHF19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[106]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[361]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[92]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[351]

Drug(s) Affected By Proline/serine-rich coiled-coil protein 1 (PSRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[362]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]

Drug(s) Affected By Protein aurora borealis (BORA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[256]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[98]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Interleukin-20 receptor subunit beta (IL20RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[363]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[364]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[365]

Drug(s) Affected By Protein MCM10 homolog (MCM10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[122]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Mitomycin	DMH0ZJE	Breast cancer	2C60-2C65	Approved	[122]

Drug(s) Affected By Suppressor APC domain-containing protein 2 (SAPCD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[365]

Drug(s) Affected By Condensin-2 complex subunit G2 (NCAPG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[366]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]

Drug(s) Affected By Cytoskeleton-associated protein 2-like (CKAP2L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[367]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[368]

Drug(s) Affected By Kinetochore protein Spc24 (SPC24)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[369]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[370]

Drug(s) Affected By Holliday junction recognition protein (HJURP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Methamphetamine	DMPM4SK	Anxiety		Approved	[371]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[372]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[343]

Drug(s) Affected By Protein DENND6B (DENND6B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[334]

Drug(s) Affected By DEP domain-containing protein 1B (DEPDC1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[77]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[92]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Retinol dehydrogenase 5 (RDH5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[373]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[364]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[333]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[334]

Drug(s) Affected By RAD51-associated protein 1 (RAD51AP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[197]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Sororin (CDCA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[186]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Aurora kinase B (AURKB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[256]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[57]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[212]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[99]

Drug(s) Affected By Proline-rich protein 11 (PRR11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[349]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]

Drug(s) Affected By Lymphokine-activated killer T-cell-originated protein kinase (PBK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[374]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]

Drug(s) Affected By Tetratricopeptide repeat protein 14 (TTC14)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[183]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[375]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[376]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[333]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[300]

Drug(s) Affected By Serine protease FAM111A (FAM111A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[373]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[377]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]

Drug(s) Affected By Cell division cycle-associated protein 3 (CDCA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By Kinesin-like protein KIF2C (KIF2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[378]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By BRCA1-associated RING domain protein 1 (BARD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]

Drug(s) Affected By Condensin complex subunit 3 (NCAPG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[298]

Drug(s) Affected By Protein PIMREG (PIMREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[101]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[72]

Drug(s) Affected By Kinesin-like protein KIFC1 (KIFC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Nucleolar and spindle-associated protein 1 (NUSAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[62]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[273]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]

Drug(s) Affected By Rac GTPase-activating protein 1 (RACGAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[71]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By DNA replication factor Cdt1 (CDT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[59]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]

Drug(s) Affected By Protein-serine O-palmitoleoyltransferase porcupine (PORCN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[379]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[344]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[380]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[333]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[334]

Drug(s) Affected By Protein FAM83D (FAM83D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[360]

Drug(s) Affected By Fanconi anemia group E protein (FANCE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[81]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[370]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[333]

Drug(s) Affected By Kinetochore protein Spc25 (SPC25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[61]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[272]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[121]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]

Drug(s) Affected By Inner centromere protein (INCENP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[343]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[351]

Drug(s) Affected By Anillin (ANLN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Kinesin-like protein KIF15 (KIF15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Centromere protein M (CENPM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[343]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[354]

Drug(s) Affected By Structural maintenance of chromosomes protein 4 (SMC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[182]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[118]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[73]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]

Drug(s) Affected By Fanconi anemia group I protein (FANCI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[381]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]

Drug(s) Affected By Histone chaperone ASF1B (ASF1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[360]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]

Drug(s) Affected By Protein downstream neighbor of Son (DONSON)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[382]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[354]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[218]
Vinblastine	DM5TVS3	Advanced cancer	2A00-2F9Z	Approved	[383]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[351]

Drug(s) Affected By Carboxypeptidase A4 (CPA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[384]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[96]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[260]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[82]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[112]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[370]

Drug(s) Affected By F-box only protein 5 (FBXO5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[65]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[137]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[79]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]

Drug(s) Affected By Targeting protein for Xklp2 (TPX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[360]

Drug(s) Affected By Exonuclease 1 (EXO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[359]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[107]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[110]

Drug(s) Affected By DNA replication complex GINS protein PSF2 (GINS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[109]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By Small kinetochore-associated protein (KNSTRN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[216]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[111]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[295]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[344]

Drug(s) Affected By Transforming acidic coiled-coil-containing protein 3 (TACC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[385]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[8]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[124]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[80]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[386]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[387]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[277]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[388]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[261]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[296]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[181]
Selenium	DM25CGV	N. A.	N. A.	Approved	[108]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[143]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[389]

Drug(s) Affected By Cyclin-dependent kinase 4 inhibitor B (CDKN2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[141]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[297]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[348]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[390]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[69]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[60]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[391]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[392]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[393]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[304]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[394]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[395]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[276]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[396]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[397]

Drug(s) Affected By G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[192]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[252]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[194]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[211]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[242]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[60]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[320]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[398]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[399]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[400]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 2A (CDKN2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[297]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[103]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[401]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[392]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[402]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[403]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[404]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[405]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[315]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[406]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[296]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[233]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[144]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[242]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[266]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[407]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Modulator	[1]
Cyclin-dependent kinase 6 (CDK6)	TTO0FDJ	CDK6_HUMAN	Modulator	[1]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[4]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Protein Interaction/Cellular Processes	[6]
Anillin (ANLN)	OTXJY54C	ANLN_HUMAN	Gene/Protein Processing	[7]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Gene/Protein Processing	[8]
Aurora kinase A (AURKA)	OTMX0HYT	AURKA_HUMAN	Gene/Protein Processing	[7]
Aurora kinase B (AURKB)	OTIY4VHU	AURKB_HUMAN	Gene/Protein Processing	[7]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[7]
Borealin (CDCA8)	OT17D55D	BOREA_HUMAN	Gene/Protein Processing	[7]
BRCA1-associated RING domain protein 1 (BARD1)	OTTC0Z9Y	BARD1_HUMAN	Gene/Protein Processing	[7]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Protein Interaction/Cellular Processes	[7]
Cadherin-2 (CDH2)	OTH0Y56P	CADH2_HUMAN	Gene/Protein Processing	[7]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
• [2] ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [3] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [4] Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.
• [5] Progress with palbociclib in breast cancer: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Feb;9(2):83-105.
• [6] Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
• [7] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [8] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [9] Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
• [10] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [13] Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [15] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [16] Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
• [19] Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
• [20] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [21] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [22] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [23] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [24] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [25] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [26] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [27] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [28] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [29] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [30] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [31] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [32] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [33] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [34] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [35] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [36] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [37] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [38] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [39] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [40] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [41] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [42] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [43] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [44] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [45] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [46] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [47] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [48] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [49] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [50] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [51] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [52] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [53] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [54] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [55] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [56] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [57] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [58] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [59] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [60] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [61] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [62] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [63] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [64] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [65] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [66] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [67] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [68] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [69] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [70] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [71] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [72] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [73] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [74] Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area in bladder cancer. Cancer Lett. 2006 Sep 8;241(1):93-101. doi: 10.1016/j.canlet.2005.10.014. Epub 2005 Dec 9.
• [75] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [76] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [77] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [78] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [79] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [80] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [81] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [82] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [83] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [84] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [85] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [86] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [87] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [88] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [89] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [90] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [91] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [92] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [93] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [94] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [95] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [96] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [97] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [98] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [99] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [100] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [101] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [102] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [103] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [104] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [105] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [106] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [107] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [108] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [109] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [110] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [111] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [112] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [113] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [114] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [115] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [116] CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Neuropharmacology. 2006 Jun;50(8):1041-7. doi: 10.1016/j.neuropharm.2006.02.004. Epub 2006 Mar 30.
• [117] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [118] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [119] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [120] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [121] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [122] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [123] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [124] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [125] Differential effects of omega-3 and omega-6 Fatty acids on gene expression in breast cancer cells. Breast Cancer Res Treat. 2007 Jan;101(1):7-16. doi: 10.1007/s10549-006-9269-x. Epub 2006 Jul 6.
• [126] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [127] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [128] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [129] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [130] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [131] Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
• [132] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [133] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [134] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [135] Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol. 2009 Feb;42(2):87-103. doi: 10.1677/JME-08-0076. Epub 2008 Nov 4.
• [136] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [137] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [138] Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
• [139] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [140] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [141] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [142] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [143] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [144] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [145] Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
• [146] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [147] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [148] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [149] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [150] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [151] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [152] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [153] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [154] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [155] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [156] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
• [157] Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007 Apr;55(4):310-7. doi: 10.1016/j.phrs.2006.12.009. Epub 2007 Jan 14.
• [158] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [159] AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett. 1996 Nov 4;396(2-3):323-6. doi: 10.1016/0014-5793(96)01124-6.
• [160] Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res. 2006 Sep 1;66(17):8829-37. doi: 10.1158/0008-5472.CAN-06-0540.
• [161] Delivery method, target gene structure, and growth properties of target cells impact mutagenic responses to reactive nitrogen and oxygen species. Chem Res Toxicol. 2012 Apr 16;25(4):873-83. doi: 10.1021/tx2004882. Epub 2012 Feb 21.
• [162] Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
• [163] E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014 Nov;45(5):2033-43. doi: 10.3892/ijo.2014.2609. Epub 2014 Aug 19.
• [164] Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
• [165] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [166] Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
• [167] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [168] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [169] Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
• [170] Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
• [171] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [172] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [173] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [174] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [175] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [176] Comparison of replicative senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett. 2005 Jul 4;579(17):3651-9. doi: 10.1016/j.febslet.2005.05.056.
• [177] Folic acid modulates cancer-associated micro RNAs and inflammatory mediators in neoplastic and non-neoplastic colonic cells in a different way. Mol Nutr Food Res. 2017 Dec;61(12). doi: 10.1002/mnfr.201700260. Epub 2017 Nov 9.
• [178] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [179] Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15;66(24):12009-18.
• [180] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [181] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [182] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [183] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [184] Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells. Pharmacol Res. 2006 Aug;54(2):91-6. doi: 10.1016/j.phrs.2006.02.010. Epub 2006 Mar 8.
• [185] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [186] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [187] Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines. Jpn J Cancer Res. 2001 Oct;92(10):1133-7. doi: 10.1111/j.1349-7006.2001.tb01069.x.
• [188] HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase II and . Chem Res Toxicol. 2018 Feb 19;31(2):137-144. doi: 10.1021/acs.chemrestox.7b00302. Epub 2018 Jan 8.
• [189] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [190] Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry. 2011 Apr 19;50(15):3240-9. doi: 10.1021/bi200094z. Epub 2011 Mar 28.
• [191] Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1552-6. doi: 10.1111/j.1525-1438.2006.00626.x.
• [192] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [193] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [194] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [195] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [196] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [197] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [198] Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 2010 Jul;72(7):869-74.
• [199] Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
• [200] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [201] Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Mar 13;380(3):614-9. doi: 10.1016/j.bbrc.2009.01.134. Epub 2009 Jan 27.
• [202] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [203] Inhibition of interleukin-1-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2. Oncotarget. 2016 Sep 20;7(38):61438-61457. doi: 10.18632/oncotarget.11367.
• [204] Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
• [205] The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol. 2003 Jan;120(2):315-24. doi: 10.1046/j.1365-2141.2003.03971.x.
• [206] Mechanisms of tissue factor induction by the uremic toxin indole-3 acetic acid through aryl hydrocarbon receptor/nuclear factor-kappa B signaling pathway in human endothelial cells. Arch Toxicol. 2019 Jan;93(1):121-136.
• [207] Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 2000 May 15;69(9):1830-6. doi: 10.1097/00007890-200005150-00017.
• [208] Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J Thromb Haemost. 2003 May;1(5):1089-95. doi: 10.1046/j.1538-7836.2003.00217.x.
• [209] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [210] Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999 Jul;13(7):1062-70. doi: 10.1038/sj.leu.2401448.
• [211] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [212] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [213] Collagen and elastin changes in D-penicillamine-induced pseudoxanthoma elasticum-like skin. Br J Dermatol. 1986 Mar;114(3):381-8. doi: 10.1111/j.1365-2133.1986.tb02832.x.
• [214] The effects of a novel synthetic retinoid, seletinoid G, on the expression of extracellular matrix proteins in aged human skin in vivo. Clin Chim Acta. 2005 Dec;362(1-2):161-9. doi: 10.1016/j.cccn.2005.06.016. Epub 2005 Aug 1.
• [215] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [216] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [217] Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004 Jun 15;64(12):4218-26.
• [218] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [219] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [220] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [221] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [222] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [223] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [224] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [225] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [226] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [227] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [228] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [229] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [230] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [231] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [232] Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway. Cancer Biol Ther. 2010 Sep 15;10(6):632-43. doi: 10.4161/cbt.10.6.12654. Epub 2010 Sep 13.
• [233] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [234] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [235] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [236] Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2. Biochem Biophys Res Commun. 2019 Jun 11;513(4):834-840. doi: 10.1016/j.bbrc.2019.04.081. Epub 2019 Apr 16.
• [237] Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
• [238] ?9-tetrahydrocannabinol inhibits epithelial-mesenchymal transition and metastasis by targeting matrix metalloproteinase-9 in endometrial cancer. Oncol Lett. 2018 Jun;15(6):8527-8535. doi: 10.3892/ol.2018.8407. Epub 2018 Apr 2.
• [239] Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
• [240] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [241] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
• [242] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [243] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [244] TGF-1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway. Chem Biol Interact. 2020 Nov 1;331:109249. doi: 10.1016/j.cbi.2020.109249. Epub 2020 Sep 24.
• [245] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [246] 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detect Prev. 2004;28(6):433-42. doi: 10.1016/j.cdp.2004.08.001.
• [247] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [248] 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
• [249] Quercetin protected against isoniazide-induced HepG2 cell apoptosis by activating the SIRT1/ERK pathway. J Biochem Mol Toxicol. 2019 Sep;33(9):e22369. doi: 10.1002/jbt.22369. Epub 2019 Jul 23.
• [250] Drug-induced liver injury: Oltipraz and C2-ceramide intervene HNF-1/GSTA1 expression via JNK signaling pathway. J Appl Toxicol. 2021 Dec;41(12):2011-2020. doi: 10.1002/jat.4181. Epub 2021 May 6.
• [251] A Study of Gentianae Radix et Rhizoma Class Differences Based on Chemical Composition and Core Efficacy. Molecules. 2023 Oct 17;28(20):7132. doi: 10.3390/molecules28207132.
• [252] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [253] Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence. Int J Biochem Cell Biol. 2003 Feb;35(2):246-54. doi: 10.1016/s1357-2725(02)00129-2.
• [254] Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
• [255] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [256] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [257] [Construction of subtracted cDNA library in human Jurkat T cell line induced by arsenic trioxide in vitro]. Zhonghua Yu Fang Yi Xue Za Zhi. 2003 Nov;37(6):403-7.
• [258] Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem. 2003 May 23;278(21):19509-17. doi: 10.1074/jbc.M300511200. Epub 2003 Mar 5.
• [259] Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). Ann Hematol. 2018 Jan;97(1):83-93. doi: 10.1007/s00277-017-3163-y. Epub 2017 Nov 20.
• [260] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [261] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [262] Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
• [263] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [264] Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
• [265] DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
• [266] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [267] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [268] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [269] Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32. doi: 10.1073/pnas.1210037109. Epub 2012 Oct 29.
• [270] Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res. 2000 Jun 1;60(11):3065-71.
• [271] Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 2006 Jul 1;66(13):6615-21. doi: 10.1158/0008-5472.CAN-05-4566.
• [272] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [273] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [274] Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
• [275] Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
• [276] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [277] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [278] Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
• [279] Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
• [280] Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
• [281] Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
• [282] Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
• [283] Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
• [284] Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
• [285] Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
• [286] Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
• [287] Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
• [288] Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
• [289] Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28.
• [290] SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1;102(3):795-801. doi: 10.1182/blood-2002-10-3023. Epub 2003 Mar 20.
• [291] Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006 Nov 15;12(22):6817-25. doi: 10.1158/1078-0432.CCR-06-1354.
• [292] HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2023 Aug 23;45(9):7011-7026. doi: 10.3390/cimb45090443.
• [293] Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 2010 Feb 15;16(4):1149-58. doi: 10.1158/1078-0432.CCR-09-2416. Epub 2010 Feb 9.
• [294] Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
• [295] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [296] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [297] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [298] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [299] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [300] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [301] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [302] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [303] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [304] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [305] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [306] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [307] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [308] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [309] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [310] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [311] Nuclear proteome analysis of cisplatin-treated HeLa cells. Mutat Res. 2010 Sep 10;691(1-2):1-8. doi: 10.1016/j.mrfmmm.2010.06.002. Epub 2010 Jun 9.
• [312] Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis. Gynecol Endocrinol. 2005 Mar;20(3):127-31. doi: 10.1080/09513590400021086.
• [313] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [314] Mitophagy inhibits proliferation by decreasing cyclooxygenase-2 (COX-2) in arsenic trioxide-treated HepG2 cells. Environ Toxicol Pharmacol. 2016 Jul;45:212-21.
• [315] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [316] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [317] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [318] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [319] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [320] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [321] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [322] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [323] Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec;1(2):141-9.
• [324] Differentiation-associated alteration in gene expression of importins and exportins in human leukemia HL-60 cells. Biomed Res. 2008 Jun;29(3):141-5. doi: 10.2220/biomedres.29.141.
• [325] DNA microarray analysis of changes in gene expression induced by 1,25-dihydroxyvitamin D3 in human promyelocytic leukemia HL-60 cells. Biomed Res. 2006 Jun;27(3):99-109. doi: 10.2220/biomedres.27.99.
• [326] Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
• [327] PLK1 targets NOTCH1 during DNA damage and mitotic progression. J Biol Chem. 2019 Nov 22;294(47):17941-17950. doi: 10.1074/jbc.RA119.009881. Epub 2019 Oct 9.
• [328] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [329] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [330] Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010 Oct 6;188(1):214-9.
• [331] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [332] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [333] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [334] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [335] A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):904-12. doi: 10.1016/j.ijrobp.2008.10.032.
• [336] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [337] Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2004 May 4;101(18):7199-204.
• [338] Riboflavin depletion impairs cell proliferation in adult human duodenum: identification of potential effectors. Dig Dis Sci. 2011 Apr;56(4):1007-19. doi: 10.1007/s10620-010-1374-3. Epub 2010 Sep 17.
• [339] Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene. 2006 Aug 28;25(38):5315-25. doi: 10.1038/sj.onc.1209679.
• [340] Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Res. 2004 Jan 1;64(1):370-7. doi: 10.1158/0008-5472.can-03-3029.
• [341] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [342] Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer. 2009 Apr 22;8:26. doi: 10.1186/1476-4598-8-26.
• [343] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [344] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [345] [Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):710-715. doi: 10.7534/j.issn.1009-2137.2018.03.013.
• [346] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [347] Histopathologic and immunohistochemical features in human skin after exposure to nitrogen and sulfur mustard. Am J Dermatopathol. 1998 Feb;20(1):22-8. doi: 10.1097/00000372-199802000-00005.
• [348] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [349] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [350] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [351] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [352] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [353] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [354] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [355] Differential responses to retinoic acid and endocrine disruptor compounds of subpopulations within human embryonic stem cell lines. Differentiation. 2012 Nov;84(4):330-43. doi: 10.1016/j.diff.2012.07.006. Epub 2012 Aug 18.
• [356] Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells. Cell Biol Toxicol. 2019 Aug;35(4):361-371. doi: 10.1007/s10565-018-09458-0. Epub 2019 Jan 5.
• [357] In vitro hydroquinone-induced instauration of histone bivalent mark on human retroelements (LINE-1) in HL60 cells. Toxicol In Vitro. 2017 Apr;40:1-10. doi: 10.1016/j.tiv.2016.12.007. Epub 2016 Dec 13.
• [358] Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol In Vitro. 2010 Sep;24(6):1696-704. doi: 10.1016/j.tiv.2010.05.017. Epub 2010 May 26.
• [359] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [360] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [361] Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor . Toxicol Appl Pharmacol. 2020 Jul 15;399:115030. doi: 10.1016/j.taap.2020.115030. Epub 2020 May 6.
• [362] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [363] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [364] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [365] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [366] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [367] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [368] RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin. Toxicol Appl Pharmacol. 2018 Oct 1;356:44-53.
• [369] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [370] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [371] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [372] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [373] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [374] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [375] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [376] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [377] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [378] DNA double-strand breaks and Aurora B mislocalization induced by exposure of early mitotic cells to H(2)O(2) appear to increase chromatin bridges and resultant cytokinesis failure. Free Radic Biol Med. 2017 Jul;108:129-145. doi: 10.1016/j.freeradbiomed.2017.03.025. Epub 2017 Mar 24.
• [379] The aquaglyceroporin AQP9 contributes to the sex-specific effects of in utero arsenic exposure on placental gene expression. Environ Health. 2017 Jun 14;16(1):59. doi: 10.1186/s12940-017-0267-8.
• [380] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [381] Ouabain, a cardiac glycoside, inhibits the Fanconi anemia/BRCA pathway activated by DNA interstrand cross-linking agents. PLoS One. 2013 Oct 4;8(10):e75905. doi: 10.1371/journal.pone.0075905. eCollection 2013.
• [382] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [383] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [384] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [385] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [386] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [387] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [388] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [389] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [390] Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31.
• [391] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [392] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [393] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [394] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [395] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [396] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [397] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [398] Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol. 2002 Feb 1;436(1-2):7-13. doi: 10.1016/s0014-2999(01)01577-1.
• [399] Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. Exp Cell Res. 2004 Jul 1;297(1):68-81. doi: 10.1016/j.yexcr.2004.02.017.
• [400] [P27(Kip1), cyclin E and endogenous TGF-beta1 changes in apoptosis of NB4 cells induced by As(2)O(3) and/or TGF-beta1 and their significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):74-9.
• [401] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [402] [Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide]. Ai Zheng. 2004 Jun;23(6):626-30.
• [403] p16 loss facilitate hydroquinone-induced malignant transformation of TK6 cells through promoting cell proliferation and accelerating the cell cycle progression. Environ Toxicol. 2021 Aug;36(8):1591-1599. doi: 10.1002/tox.23155. Epub 2021 May 1.
• [404] Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol. 2008;47(6):1062-70.
• [405] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [406] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [407] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.